All In MedTech

Device Trial Radar · NCT07338708

Visual Outcomes and Quality of Life After Vivity EDOF IOL Implantation in Early-Stage Keratoconus

Assessment of Tolerance and Visual Outcomes After Bilateral Implantation of a Premium Type Intraocular Lens (Acrysof IQ Vivity IOL) in Patients With Cataract and Mild Keratoconus

Last checked: Nov 20, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Sep 17, 2024

Primary completion

May 13, 2025

Study completion May 13, 2025

Sponsor

Lead sponsor
Azienda Ospedaliera Universitaria Integrata VeronaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 14, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if the Vivity Extended Depth of Focus intraocular lens works to improve vision in adults with cataracts and early-stage keratoconus. It will also learn about the safety and tolerance of this premium lens in patients with mild corneal irregularities. The main questions it aims to answer are: * Does the Vivity EDOF lens provide good distance vision (20/25 or better) in the dominant eye at 3 months after surgery? * Does it improve vision at intermediate and near distances compared to before surgery? * Does it preserve contrast sensitivity and optical quality despite mild corneal irregularities? * What is the patient-reported quality of life and satisfaction after implantation? * What visual disturbances (such as halos) do participants experience? All participants will: * Receive the Vivity EDOF intraocular lens (or its toric version if astigmatism is present) in both eyes during standard cataract surgery, with the second eye operated within 7 days; * Undergo comprehensive eye examinations before surgery including vision testing, corneal imaging, and optical quality measurements; * Attend a follow-up visit at 3 months after surgery for detailed vision testing at multiple distances, contrast sensitivity testing under different lighting conditions, halo assessment, and quality-of-life questionnaires.

Conditions

  • Cataract
  • Keratoconic Subjects

Interventions

  • Extended Depth of Focus Intraocular Lens ImplantationDevice

    Bilateral implantation of the AcrySof IQ Vivity (Alcon, Fort Worth, TX, USA) Extended Depth of Focus (EDOF) intraocular lens during phacoemulsification cataract surgery. The Vivity is a single-piece hydrophobic acrylic IOL (6.0 mm optic, 13.0 mm overall length) featuring non-diffractive X-WAVE wavefront-shaping technology with a slightly elevated central plateau (\~1 µm) and surrounding curvature modulation to extend focal range. It incorporates UV and blue light filtering with refractive index 1.55 at 35°C. The spherical model (powers +15.0 D to +25.0 D) or toric model (cylinder 1.03 D to 4.11 D at IOL plane) is selected based on corneal astigmatism. IOL power calculated using Kane formula targeting emmetropia. Surgery performed with 2.2 mm incision under topical anesthesia, with second-eye surgery within 7 days. This study specifically evaluates performance in patients with early-stage stable keratoconus.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Distance-Corrected Visual Acuity in the Dominant EyeTime frame: 3 months after surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Azienda Ospedaliera Integrata di Verona

    Verona, Verona, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.